News Sentiment

SION sentiment intelligence

Sionna Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 73 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 49.41 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+9.1% over one week, +32.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Sionna Therapeutics (SION) Stock Looks Pricey On Assets But Strong On Returns

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 9.1% Price confirming higher
Trend fit Trend active 32.5% over four weeks
Fair value 68.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 44
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 8
Investing.com Nigeria 4
Finviz 4
simplywall.st 3
StocksToTrade 3
Investing.com 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 20
Analyst action 6
Balance sheet 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 73
StocksToTrade Direct company coverage

SION Jumps As Sionna Therapeutics Draws Trader Attention

Sionna Therapeutics Inc. (SION) stock has surged by 11.26% due to positive cystic fibrosis drug development news. Despite being a pre-revenue biotech with negative earnings and cash burn, its strong balance sheet with low debt and high liquidity makes it a high-risk, high-reward

Tone
Positive 73/100
Event
Balance sheet
Published
18 Jul 2026 12:09
Source
StocksToTrade
StocksToTrade Direct company coverage

SION Jumps As Sionna Therapeutics Stock Extends Breakout

Sionna Therapeutics Inc. (SION) stock jumped over 11% following positive developments in its cystic fibrosis pipeline, signaling increased investor confidence. The stock showed strong technical breakout from the low-$40s to the $50 area, driven by aggressive buying and short cove

Tone
Positive 72/100
Event
Market update
Published
18 Jul 2026 11:48
Source
StocksToTrade
GuruFocus Direct company coverage

Sionna Therapeutics (SION) Sees 9.2% Surge in Stock Price

Sionna Therapeutics (SION) experienced a 9.2% surge in its stock price, reaching $49.44, driven by positive investor sentiment and developments in its biotechnology focus on cystic fibrosis treatments. Despite this gain, the company holds a low GF Score™ of 12/100, indicating pro

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 18:39
Source
GuruFocus
Investing.com South Africa Direct company coverage

Sionna Therapeutics stock hits all-time high at 48.66 USD By Investing.com

Sionna Therapeutics (SION) stock has reached an all-time high of $48.66, marking a 147% total return over the past year and achieving a market capitalization of $2.04 billion. Analyst ratings vary, with Citizens and Stifel maintaining "Outperform" and "Buy" ratings respectively,

Tone
Positive 72/100
Event
Analyst action
Published
17 Jul 2026 15:39
Source
Investing.com South Africa
GuruFocus Direct company coverage

Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc

Orbimed Advisors LLC recently reduced its stake in Sionna Therapeutics Inc by selling 85,918 shares at $44.86 per share. Despite this reduction, Sionna Therapeutics remains a significant holding (2.2% of the portfolio) for Orbimed, a healthcare investment firm with $15 billion in

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jul 2026 01:42
Source
GuruFocus
Gotrade Direct company coverage

Sionna Therapeutics, Inc. Common Stock (SION) Stock Price Today: $42.59

This article provides details on Sionna Therapeutics, Inc. (SION) stock, including its current price of $42.59 and key financial fundamentals like market capitalization ($1.98B) and P/E ratio. It also outlines how to buy SION stock through the Gotrade app, explains that SION does

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 03:48
Source
Gotrade
Moomoo Direct company coverage

Sionna Therapeutics(SION.US) Director Sells US$3.85 Million in Common Stock

A director at Sionna Therapeutics (SION.US) recently sold common stock valued at US$3.85 million. This insider transaction indicates a significant divestment by a key individual associated with the company. Investors often monitor such sales for insights into a company's financia

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 09:10
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form 4 Sionna Therapeutics Inc For: 9 July By Investing.com

This article announces a Form 4 filing for Sionna Therapeutics Inc. on July 9th, as reported by Investing.com. It is a brief, factual announcement without further details within the main article text, which primarily serves as a placeholder for the filing. The article is part of

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 02:09
Source
Investing.com Nigeria
Quartr Direct company coverage

Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 Summary

Sionna Therapeutics presented at the Jefferies Global Healthcare Conference 2026, outlining its strategy to revolutionize cystic fibrosis treatment by targeting the NBD1 region of the CFTR protein. The company highlighted its scientific approach with differentiated NBD1 stabilize

Tone
Positive 75/100
Event
Market update
Published
09 Jul 2026 10:42
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 4 Sionna Therapeutics Inc For: 7 July By Investing.com

This article from Investing.com is a regulatory filing update, announcing the Form 4 for Sionna Therapeutics Inc. The filing date is listed as July 7. The content is primarily a placeholder for the filing, mentioning the company's stock symbol SION.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
08 Jul 2026 08:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

Sionna Therapeutics CLO Jennifer Fitzpatrick sells $446k in stock

Jennifer Fitzpatrick, CLO of Sionna Therapeutics (NASDAQ:SION), sold 10,250 shares of company stock for $446,862 on July 6, 2026, after exercising options. The sale was executed under a Rule 10b5-1 trading plan, with the stock currently trading near its 52-week high and Investing

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:40
Source
Investing.com
TradingView Direct company coverage

ETFs Investing in Sionna Therapeutics, Inc. Stocks

This article lists various ETFs that include Sionna Therapeutics, Inc. (SION) stocks in their holdings. The ETFs are sorted by market value and provide details such as issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The information aims to help i

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 23:09
Source
TradingView
Investing.com UK Direct company coverage

Form 4 Sionna Therapeutics Inc For: 2 July By Investing.com

This article announces the filing of Form 4 by Sionna Therapeutics Inc. for July 2nd, as reported by Investing.com. It is a brief financial news update indicating a disclosure filing from the company to the SEC. The content provides minimal detail beyond the announcement of the f

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 19:40
Source
Investing.com UK
Investing.com Direct company coverage

Sionna Therapeutics director Thompson sells $5.27m in stock

Peter A. Thompson, a director at Sionna Therapeutics (NASDAQ:SION), has sold 115,844 shares of common stock for approximately $5.27 million, through a Rule 10b5-1 trading plan. This transaction, reported on June 30, 2026, occurred while the stock was trading at $45.50 per share,

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 21:39
Source
Investing.com
Finviz Direct company coverage

SION - Sionna Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings for Sionna Therapeutics Inc (SION), along with comprehensive financial data, stock performance metrics, and analyst ratings. It details the company's market capitalization, income, sales, insider and institutional ownership, and variou

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 06:39
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Sionna Therapeutics, Inc. – NASDAQ:SION

This article focuses on the enterprise value to EBITDA forward of Sionna Therapeutics, Inc. (NASDAQ: SION). The content appears to be a financial data page from TradingView, indicating that the market for SION was closed with no trades at the time of publication.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Sionna Therapeutics, Inc. – NASDAQ:SION

The article focuses on the enterprise value to revenue forward metric for Sionna Therapeutics, Inc. (NASDAQ: SION). It provides a snapshot of the company's financial overview within the health technology and biotechnology sector on the Nasdaq Stock Market. The page appears to be

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 21:09
Source
TradingView
Finviz Direct company coverage

SION - Sionna Therapeutics Inc Options

This article provides detailed financial data and performance metrics for Sionna Therapeutics Inc. (SION). It includes key financial figures such as market cap, income, sales, EPS, and various ratios, alongside stock performance, insider and institutional ownership, and analyst r

Tone
Negative 42/100
Event
Earnings
Published
01 Jul 2026 17:09
Source
Finviz